UnitedHealth Shares Plunge On Weak Earnings And Lackluster Revenue Guidance

UnitedHealth reported a collapse in fourth-quarter net earnings to $10 million (from $5.54 billion year‑ago) with adjusted Q4 EPS falling to $2.11 from $6.81, while Q4 revenue rose to $113.22 billion from $100.81 billion. For full-year 2025 net earnings attributable to the company were $12.06 billion (adjusted EPS $16.35) on revenue of $447.6 billion, and management guided FY2026 to revenue above $439.0 billion, operating earnings >$24.0 billion, GAAP EPS >$17.10, adjusted EPS >$17.75 and operating cash flow >$18 billion. The shock to profitability sent the stock down sharply in pre-market trade (about -15.15% to $297.84) and creates near-term downside risk despite a solid top line.

Analysis

Market structure: UNH’s shock Q4 collapse is a classic idiosyncratic hit that benefits short-term volatility players and competing insurers able to claim stability—consider HUM and CI as relative beneficiaries over 2–12 weeks if flows rotate away from UNH. PBM/pharmacy names (CVS, WBA) may see mixed flows depending on how much of the hit is Optum/pharmacy‑margin related; UNH credit spreads should widen near term, pushing some fixed‑income demand into high‑grade corporates.

Risk assessment: Tail risks include a material Medicare Advantage funding cut or a multi‑quarter Optum reserve/legal charge (low probability but >$5–10B impact), and a sustained loss of MA share to competitors over 12–24 months. Immediate (days) risk is forced deleveraging/vol‑driven selling; short term (weeks–months) risk is continued repricing of FY26 guidance vs market expectations; long term (quarters) fundamentals (cashflow guidance >$18B, adjusted EPS >$17.75) argue for recovery if no new regulatory shock.

Trade implications: Tactical short via 30–90 day put spreads on UNH to capture IV and momentum (size 1–3% portfolio) while hedging with a 2% long position in HUM or CI as a pair trade (long Humana, short UNH) to play MA exposure divergence. If you want asymmetric long exposure, consider buying 9–12 month UNH LEAPS (buying OTM 12–18% strikes) sized 1–2% for recovery capture and sell 60–90 day calls to fund part of the premium.

Contrarian: The market may be overdiscounting FY26 as guidance still implies adjusted EPS >$17.75 and operating earnings >$24B—if UNH holds cash flow >$18B, downside below $280 could be an idiosyncratic buying opportunity. History: large one‑time reserve/legal hits at insurers often produce 6–12 month mean reversion; watch options IV (sell premium after 30–45 days) and credit‑spread normalization as catalysts for reversal.

Key Decisions for Investors

• Establish a tactical short position in UNH via a 60‑day put spread (e.g., buy 1x 300 strike, sell 1x 270 strike if premarket ~298) sized at 1–3% of portfolio to capture near‑term downside and elevated IV; reassess at 2 weeks or if UNH rallies above $330.
• Construct a pair trade: short UNH (1–2% net exposure) and go long HUM (Humana) 2% as relative‑value MA exposure; rebalance if spread between shares widens >15% or after 3 months.
• If your horizon is 6–12 months, size a small long in UNH LEAPS (buy 12‑month OTM calls ~15% below current spot) sized 1–2% and finance by selling 60–90 day calls (covered or naked depending on risk) to exploit IV term structure.
• Reduce exposure to broad managed‑care ETF XHE or IHF by 3–5% and rotate into defensive healthcare (JNJ 2–3%, PFE 2%) and hospital operators (CIH or HCA 1–2%) until UNH/sector volatility subsides.
• Monitor these triggers in next 30–60 days before adding size: UNH free cash flow prints ≥$18B, adjusted EPS reaffirmation >$17.75, or MD&A disclosure that no additional >$3–5B reserve/legal charges are expected—if met, close shorts and redeploy into long UNH exposure.